Latest News

Targeted therapy proves effective against aggressive rare blood cancer

A multi-institutional clinical trial has given good results for a targeted therapy to treat a rare, aggressive blood cancer known as blastic plasmacytoid dendritic-cell neoplasm (BPDCN). Details on the trial, which supported Food and Drug Administration approval of the tagraxofusp therapy in December 2018, have been published in the New England Journal of Medicine.

Source link

Related posts

Blue Shield of California teams up with Solera to relaunch Wellvolution


How Ordering From Local Stores Can Curb CO2 Emissions


Drug trial seeking first ever treatment for dangerous side effect of Prader-Willi syndrome


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World